Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer

In an interview with Urology Times®, Nitin K. Yerram, MD, discusses the miR Sentinel Prostate Cancer Test, which is a standalone urine-based diagnostic biomarker for prostate cancer.

“There's really a need in this area when it comes down to something better; we need something better than PSA,” Yerram explained. “The Sentinel test is a new test that looks at patients' urine and is able to detect almost 50 different mRNAs or RNAs that are suspicious for that specific cancer the patient may have, and [is] able to help further characterize patients as either high-risk or low-risk, or even 'no molecular evidence of prostate cancer'. It helps guide the urologist in terms of what the next steps are in terms of their diagnosis and treatment algorithms.”

Yerram is a urologic oncologist at Hackensack University Medical Center in New Jersey.